Tacrolimus and Macular oedema - a phase IV clinical study of FDA data

Summary:

Macular oedema is reported as a side effect among people who take Tacrolimus (tacrolimus), especially for people who are female, 30-39 old, also take Ciclosporin, and have Autoimmune pancytopenia.

The phase IV clinical study analyzes which people have Macular oedema when taking Tacrolimus. It is created by eHealthMe based on reports of 115,828 people who have side effects when taking Tacrolimus from the FDA, and is updated regularly.

What is Tacrolimus?

Tacrolimus has active ingredients of tacrolimus. It is often used in kidney transplant. eHealthMe is studying from 116,160 Tacrolimus users. Check the latest studies of Tacrolimus.

What is Macular oedema?

Macular oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken) is found to be associated with 432 drugs and 861 conditions by eHealthMe. Check the latest studies of Macular oedema.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

115,828 people reported to have side effects when taking Tacrolimus.
Among them, 15 people (0.01%) have Macular oedema.

Among these 15 people:

What is the gender of people who have Macular oedema when taking Tacrolimus? *

female: 84.62 %
male: 15.38 %

What is the age of people who have Macular oedema when taking Tacrolimus? *

What are other drugs people take besides Tacrolimus? *

What are other side effects people have besides Macular oedema? *

Retinal Haemorrhage (bleeding from retina): 5 people, 33.33%
Aplasia Pure Red Cell (type of anaemia affecting the precursors to red blood cells but not to white blood cells): 3 people, 20.00%
Thrombophlebitis Superficial (swelling (inflammation) of a superficial vein caused by a blood clot): 3 people, 20.00%
Drug Ineffective: 3 people, 20.00%
Visual Impairment: 2 people, 13.33%
Autoimmune Pancytopenia (abnormal deficiency in all blood cells by immune system deficiency): 2 people, 13.33%
Cataract (clouding of the lens inside the eye): 2 people, 13.33%
Corneal Lesion (an injury to the living tissue of cornea): 2 people, 13.33%
Diabetic Retinopathy (damage to the retina caused by complications of diabetes): 2 people, 13.33%
Endophthalmitis (inflammation of the internal coats of the eye): 2 people, 13.33%

What are the existing conditions these people have? *

Autoimmune Pancytopenia (abnormal deficiency in all blood cells by immune system deficiency): 5 people, 33.33%
Transplant Rejection (a transplant material is not worked): 4 people, 26.67%
Immunodeficiency Disorders: 4 people, 26.67%
Overgrowth Bacterial (extra growth due to bacteria): 3 people, 20.00%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 3 people, 20.00%
Respiratory Tract Infection: 2 people, 13.33%
Herpes Zoster: 2 people, 13.33%
Bone Marrow Conditioning Regimen: 2 people, 13.33%
Diabetes: 1 person, 6.67%
Cytomegalovirus Infection: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Tacrolimus and have Macular oedema?

- Check whether Macular oedema is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tacrolimus:

Tacrolimus (116,160 reports)

Macular oedema treatments and more:

Macular oedema (10,661 reports)

Browse all side effects of Tacrolimus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Macular oedema:

Macular oedema (432 drugs)

Browse all the conditions that are associated with Macular oedema:

Macular oedema (861 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tacrolimus (the active ingredients of Tacrolimus) and Tacrolimus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.